Impaired interferon signaling is a common immune defect in human cancer. - Wikidata - wikimedia - TriplyDB

Impaired interferon signaling is a common immune defect in human cancer.

Impaired interferon signaling is a common immune defect in human cancer.

http://www.wikidata.org/entity/Q37211332

about

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade Reflections upon human cancer immune responsiveness to T cell-based therapy Combining radiotherapy and cancer immunotherapy: a paradigm shift An immunologic portrait of cancer Genomic scale analysis of racial impact on response to IFN-alpha Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C Melanoma NOS1 expression promotes dysfunctional IFN signaling Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response.Adaptive control of innate immunity.Similar blood-borne DNA methylation alterations in cancer and inflammatory diseases determined by subpopulation shifts in peripheral leukocytes.Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design.The natural product phyllanthusmin C enhances IFN-γ production by human NK cells through upregulation of TLR-mediated NF-κB signaling.Polymorphisms in immune mediators associate with risk of cervical cancer Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas.Serum-dependent transcriptional networks identify distinct functional roles for H-Ras and N-Ras during initial stages of the cell cycle Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the IL10Rβ and IFNAR1 genes Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.Targeting the tumor microenvironment to enhance antitumor immune responses Similar source of differential blood mRNAs in lung cancer and pulmonary inflammatory diseases: calls for improved strategy for identifying cancer-specific biomarkers Oncolytic virotherapy for ovarian cancer.Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells.Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients Pro-oncogenic cytokines and growth factors are differentially expressed in the post-surgical wound fluid from malignant compared to benign breast lesions Exploiting antitumor immunity to overcome relapse and improve remission duration.Mutations of the human interferon alpha-2b (hIFNα-2b) gene in cancer patients receiving radiotherapy.Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.Gene-expression profiling in vaccine therapy and immunotherapy for cancer Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent.Cooperativity of adaptive and innate immunity: implications for cancer therapy.Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression

P2860

Q26769977-A010ACD3-EB7F-42BA-B7D1-E091D2C3358A Q27004674-59CBA8E1-7184-46AA-8AAC-8F9C4E1E3182 Q27021428-7267AECC-2B18-41D1-95C4-E1E7BA82B134 Q27028000-0E5FCA48-34E0-4A4D-A0AB-724B38F9F1C9 Q27490906-780265E8-6F0C-46B5-B8DB-FEBB65E05163 Q28478142-1F5E5CA1-D971-4AF5-A2BB-81A6E40F9973 Q30413226-A472E80D-6C97-4532-897B-F9FD465A04B0 Q30438965-E5458356-66EE-4E80-B23D-432563250496 Q33558702-9920AD1E-E6B3-4087-8D36-612E6DA9715C Q33579385-03738162-78BF-4C26-A43E-EE48346EB639 Q33688623-6B89FCD8-2DB4-48C2-8605-1E08ACB4AA21 Q33912853-44AECDCC-3D8D-4AA9-871E-D15FFDE2E173 Q33994413-1DB2873F-51E6-42D4-8112-5220DE21F455 Q34106393-9AD10F96-B994-44D7-87E6-964D09A4A209 Q34171983-A93596AC-4421-47A8-BFD4-89E3687F233C Q34345226-F181964B-D96D-4AB4-AEB1-7E3CECD1DB50 Q34618599-2AEC631A-AD33-4478-9EA3-ABED7C6D58D0 Q34914935-C108932E-F4DE-4B7D-980F-58C92DDD1A08 Q34964571-8F66781E-8D11-4D06-9BC2-DA364A293309 Q34983816-C59B3C6C-DEE2-42B9-A20C-3A8F4D420EF7 Q35044537-781E7777-445A-470E-A326-56436DA8D854 Q35107727-560107A9-9A6C-4997-A934-BEA06CD53AAA Q35110264-AB5DAE41-507F-4FAA-8D61-D32C3B866A79 Q35128818-54F5C890-84CB-4C37-A20F-489EE33223BF Q35141469-A13BE17D-9077-4AFC-8CBA-3ABC7F16F0FA Q35176307-388D29DE-D532-4D41-B8B2-F87913DC778E Q35268621-65747B2E-0FCC-4D2C-B58C-F37ED325889A Q35597082-66112546-B706-4F7A-88A8-FE541AC7EC37 Q35599302-2612C6CE-31EA-4ADA-B9ED-2CDDA206CAE2 Q35696378-008BAB44-0730-416C-97AF-90A1C51CBE49 Q35996170-563B8F7A-7E4A-4562-A3CE-05153C417AFC Q36029913-CA7AFCC4-111E-453C-8C8A-8B5ED8C3688B Q36044604-E033B618-15E8-4E4E-8B98-C20F0798C7B2 Q36057129-B9148A35-5BE8-4DEC-BCE7-9FFAB00A6984 Q36119996-927347B4-CC7D-44F9-812F-17396A10B0F3 Q36138329-3F692573-49AC-492B-8042-A941D203D9B9 Q36234001-CF02220C-98B1-4C47-95E8-A82ED7C30F8D Q36429508-C81116F5-7EB5-4A7E-B4C9-4BFEEEE151C8 Q36599823-CC687399-E677-4647-95E6-85E1D077970D Q36784394-1577B874-93A0-414A-B083-7FD23ABFA966

P2860

Impaired interferon signaling is a common immune defect in human cancer.

http://www.wikidata.org/entity/Q37211332

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impaired interferon signaling is a common immune defect in human cancer.

@en

Impaired interferon signaling is a common immune defect in human cancer.

@nl

type

label

Impaired interferon signaling is a common immune defect in human cancer.

@en

Impaired interferon signaling is a common immune defect in human cancer.

@nl

prefLabel

Impaired interferon signaling is a common immune defect in human cancer.

@en

Impaired interferon signaling is a common immune defect in human cancer.

@nl

P1433

Q37211332-117AFFE6-755C-4A1D-A69B-38324C81E9A7

P1476

Q37211332-0993B2A5-5BF5-476F-98BB-C39074071CE2

P2093

Q37211332-058A52DD-7609-4471-B184-B66B9DC801A0

Q37211332-22D20A88-7932-44FB-BB1B-4A42C591A6CC

Q37211332-24185F3B-7840-4673-9267-9ED480F34428

Q37211332-41EAB05C-8726-4FAC-820A-2034602507F4

Q37211332-4C80D71F-5237-4665-9B0D-3797AA327B95

Q37211332-4E3E4AD6-C809-422A-B233-9DBEF5739317

Q37211332-5E845037-EFCB-4032-A2D0-5AA652EA1C74

Q37211332-8751B76C-E5B8-4CBE-900C-7D6028E1FE01

Q37211332-A381B0CA-FB80-4603-B764-393E549AF171

Q37211332-A7A8BE78-FFF4-4CDF-A736-CAC3CE8C570D

P2860

Q37211332-00181DBE-45EA-4B99-A9C0-8B06B0D31CF6

Q37211332-0E26171A-AA2C-4853-BD43-7FE30590C083

Q37211332-20C407D6-2EC8-4E20-B015-266260533D0F

Q37211332-27454D99-243E-41F6-81D8-A31E17D1AC42

Q37211332-2C125BEE-82F0-4BF0-9A8F-605225C2F9E5

Q37211332-318948D1-5A92-49B1-BEA2-355896BAC310

Q37211332-4139F279-F91B-4736-A8FA-2F8FCFAD554B

Q37211332-48A4B042-AA09-4B9A-942D-B7C8BCB68670

Q37211332-49BDC65A-B28E-4EE7-92A4-EF2D783A3FB3

Q37211332-52DF3C6A-FD8F-4BBB-82C7-CCAE30D965A9

P304

Q37211332-2408F1FF-9032-49D1-A40E-08512FE89B3D

P31

Q37211332-EE87A223-63AE-4DFC-8CF1-5E3E7DAA204A

P356

Q37211332-5A9926B9-93BB-4657-8353-23D49F6A89EE

P407

Q37211332-3BED335D-3749-4287-8588-00FF2FF9F88E

P433

Q37211332-B694B6B2-1ACE-4F44-ADFA-38D4C4D4BB19

P478

Q37211332-5C03C757-33CA-444F-BC38-43FE7EE989BF

P577

Q37211332-77B0EA2B-264C-4837-82C5-CF615021E697

P5875

Q37211332-419E00BA-1476-417D-A971-AEE89CEC0704

P698

Q37211332-B3A149C3-26C7-4A84-8895-C312B2ABA813

P932

Q37211332-316D9060-F086-462C-B1C4-7C18F40022C3

P356

PNAS.0901329106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Impaired interferon signaling is a common immune defect in human cancer.

@en

P2093

Albert Koong

http://www.w3.org/2001/XMLSchema#string

Andrea K Miyahira

http://www.w3.org/2001/XMLSchema#string

Denise L Johnson

http://www.w3.org/2001/XMLSchema#string

Diana L Simons

http://www.w3.org/2001/XMLSchema#string

Frederick M Dirbas

http://www.w3.org/2001/XMLSchema#string

George A Fisher

http://www.w3.org/2001/XMLSchema#string

Ning Yan

http://www.w3.org/2001/XMLSchema#string

Peter P Lee

http://www.w3.org/2001/XMLSchema#string

Rebecca J Critchley-Thorne

http://www.w3.org/2001/XMLSchema#string

Robert W Carlson

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Stat1-mediated gene activation by PIAS1

A family of cytokine-inducible inhibitors of signalling

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection

Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Interferon gamma is required for activation-induced death of T lymphocytes.

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus.

P304

9010-9015

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0901329106

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24436457

http://www.w3.org/2001/XMLSchema#string

P698

19451644

http://www.w3.org/2001/XMLSchema#string

P932

2690021

http://www.w3.org/2001/XMLSchema#string